PML risk stratification using anti-JCV antibody index and L-selectin. - Wikidata - awgldk - TriplyDB

PML risk stratification using anti-JCV antibody index and L-selectin.

PML risk stratification using anti-JCV antibody index and L-selectin.

http://www.wikidata.org/entity/Q48938768

about

Current status of biomarker research in neurology Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Longitudinal analyses of anti-JCV antibody index for risk assessment of progressive multifocal leukoencephalopathy.Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug Diagnostic assays for polyomavirus JC and progressive multifocal leukoencephalopathy The future of multiple sclerosis treatments.Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators' perspective.JCV serology in time: 3 years of follow-up.Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologica [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].The effect of disease modifying therapies on CD62L expression in multiple sclerosis

P2860

Q26744505-7750192F-1586-44BF-AB01-8BD859DCCE6C Q30699740-0351AE34-40C2-45F4-9BDB-36C7AAB153D8 Q33693085-E3BD2B03-89DD-4468-BC63-A0AA31A680B1 Q36073992-01B9F051-E522-439B-9292-0D74B91A85F5 Q36521237-726B5F0D-1ED3-4B56-9816-D9D25C99CA2A Q36942417-AB9D3BBD-0B4D-40E5-B115-C9191A4E78F8 Q38808485-AFC6161F-CE39-4A35-9CB0-904EEE960945 Q38960854-EBD92153-0A62-4D3C-B835-B174766AD810 Q38984981-ECA3307E-3DB1-454B-A47F-FEF9A8C99F51 Q39046213-260EDAAB-C8F0-4C54-B001-EA449EE9A79B Q39263983-F0A02C34-BBCD-4A6D-8216-BC42F2C8E600 Q40039520-24EE0D06-7D02-47DA-85E8-B00B75DC3296 Q40061894-FC6F48E6-D1C9-420E-962E-D2FC652DD82A Q40067748-C5F62135-3C00-4A8E-AD82-AB2F438872C0 Q52855510-9AB20600-935F-4C1A-A6B8-F32A5158ABEB Q58711606-5DB87C77-A490-4586-8E42-D0034FF06803

P2860

PML risk stratification using anti-JCV antibody index and L-selectin.

http://www.wikidata.org/entity/Q48938768

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

PML risk stratification using anti-JCV antibody index and L-selectin.

@en

PML risk stratification using anti-JCV antibody index and L-selectin.

@nl

type

label

PML risk stratification using anti-JCV antibody index and L-selectin.

@en

PML risk stratification using anti-JCV antibody index and L-selectin.

@nl

prefLabel

PML risk stratification using anti-JCV antibody index and L-selectin.

@en

PML risk stratification using anti-JCV antibody index and L-selectin.

@nl

P1433

Q48938768-3309787C-2A0B-4842-8597-EE7E60D1CF58

P1476

Q48938768-E893500B-6B7C-421E-97F9-EB436286FDCC

P2093

Q48938768-217DE334-BBA4-4557-8EEB-EC8243F6D55C

Q48938768-22C09AE2-F828-4805-90C3-71475E2A7608

Q48938768-436A7FBE-92EC-496A-9473-D9B72DDC2220

Q48938768-4A83FF31-CA8F-4ED1-A51D-D0B0B21BF1F4

Q48938768-6ACD3465-283E-4080-BAD0-F1A067470FCA

Q48938768-75F34AD3-4FD3-4C64-BC95-8008217DFB3D

Q48938768-7D6BF1F5-F2A0-4E4A-974A-5F47CD807C87

Q48938768-8CB5308D-6497-4A2B-AE28-1866D9A92995

Q48938768-90F5082A-9AD1-424B-890F-CA92E981FE25

Q48938768-B8428A00-8F02-4E32-9E26-4EE56D774E39

P2860

Q48938768-0F891E76-3153-4F64-AAC6-567751CFBCF2

Q48938768-2788E399-A242-4945-8CD4-9607AECA7967

Q48938768-36CFCF6B-AAC0-4E27-81C1-7E93BF6FEAED

Q48938768-4DAA906A-B5AB-4778-9016-B6479F3DFA21

Q48938768-4DC7E21B-E2D3-4B11-9208-4A06C421BD12

Q48938768-707DC4EE-C0BA-4216-A929-4E01FBC180A4

Q48938768-7F2CEFAC-06C1-46F3-8601-2DA0C9287380

Q48938768-874B7433-F989-4E57-8127-CBD6F6A5D4F6

Q48938768-8AAC2B75-E1E4-4E35-B6B3-593A72412A94

Q48938768-AFC974C9-3522-47AD-93B9-C6E139870761

P304

Q48938768-E137B548-FB37-4360-ABD0-68C58F6F2D31

P31

Q48938768-0ABD8D26-5AC8-42AC-8A5C-336308B45A0F

P356

Q48938768-E145EA2D-90DF-479C-8276-A18CDA6BACF5

P433

Q48938768-93784E74-646B-4AA1-84D7-A9F24DD85422

P478

Q48938768-254DFB87-BCF3-4516-BC2B-43FC01B74608

P50

Q48938768-26269E36-5AE2-4020-8156-184E8A1B47F7

Q48938768-3B7C2521-C1C3-432B-826D-DB5A34636DEE

Q48938768-437B8A1A-FA56-46B9-A6F3-82B16550DCB3

Q48938768-46195DB9-4D0A-467B-9FAC-ECBF1846AB13

Q48938768-5D1534B9-28A2-4C55-B7ED-204EE58F4F09

Q48938768-8CFEB5EA-738A-4BD3-B6D9-483C5A5B4523

Q48938768-9E0F4C57-531B-411C-962A-66C774D80C44

Q48938768-A17054C9-28A6-4349-BBDF-CE63C0EAF366

Q48938768-DF6B5AF3-3EEA-4810-8B5B-6E3F2868F26A

Q48938768-F2DD960D-71A5-407E-AD93-04AE10975383

P577

Q48938768-03B7597C-07C7-45D9-9A66-C5AC786BA04C

P5875

Q48938768-C63A544E-8038-47F4-8DB1-3A9B0CB27ACE

P698

Q48938768-42A842B9-EB7D-4214-9F1C-E388D8D5811D

P921

Q48938768-31946949-C000-495F-A3DB-48BF48435C53

P356

1352458515607651

P1433

Multiple Sclerosis Journal

P1476

PML risk stratification using anti-JCV antibody index and L-selectin

@en

P2093

Anita Posevitz-Fejfár

http://www.w3.org/2001/XMLSchema#string

Annett Jacobi

http://www.w3.org/2001/XMLSchema#string

Björn Tackenberg

http://www.w3.org/2001/XMLSchema#string

Béatrice Pignolet

http://www.w3.org/2001/XMLSchema#string

David Brassat

http://www.w3.org/2001/XMLSchema#string

Ester Cantó

http://www.w3.org/2001/XMLSchema#string

Felix Luessi

http://www.w3.org/2001/XMLSchema#string

Ingrid Meinl

http://www.w3.org/2001/XMLSchema#string

Johanna Breuer

http://www.w3.org/2001/XMLSchema#string

Manuel Comabella

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer.

Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.

Identification and quantitation of apoptotic cells following anti-CD3 activation of murine G0 T cells.

BK virus antibody titers and intensity of infections after renal transplantation.

P304

1048-1060

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458515607651

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas Schwab

Renaud Du Pasquier

Tilman Schneider-Hohendorf

Dennis Görlich

Antonio Bertolotto

Xavier Montalban

Christoph Kleinschnitz

P577

2015-10-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282567654

http://www.w3.org/2001/XMLSchema#string

P698

26432858

http://www.w3.org/2001/XMLSchema#string

P921